Synthesis of Nirmatrelvir: Development of an Efficient, Scalable Process to Generate the Western Fragment
Organic Process Research & Development · 15.12.2023 · 27 (12) · 2240-2249
DOI: 10.1021/acs.oprd.3c00249 ↗Kurz gefasst
Fachartikel in der Zeitschrift Organic Process Research & Development, online erschienen am 25.11.2023. Verfasst von Russell F. Algera und 34 weiteren Autor:innen. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Pfizer.
Abstract (Originalsprache)
Nirmatrelvir ( 1 ), a novel and specific inhibitor of the SARS-CoV-2 3C-like protease, was developed by Pfizer scientists in mid 2020. Efforts to develop a scalable process to manufacture nirmatrelvir were undertaken with a great sense of urgency, as there were no effective treatments available for the worldwide patient population at that time. We used a convergent approach to generate this molecule. The first two steps used to generate the western fragment of nirmatrelvir from l - tert -leucine, ethyl trifluoroacetate, and a [3.1.0] bicyclic proline derivative are described here. This is the first of a series of four papers describing the commercial process of the development of nirmatrelvir.
Förderung
- Pfizer
Zitieren
APA
Algera, R. F., Allais, C., Baldwin, A. F., Becirovic, H., Bowles, P., Brown, A. R., Buske, J. M., Clarke, H. J., Do, N. M., Doyle, K., Fifer, J., Gray, K., Happe, A., Hardink, M., Hubbell, A. K., James, C., Khadamkar, H. P., Magano, J., McInturff, E. L., …, & Yu, S. (2023). Synthesis of Nirmatrelvir: Development of an Efficient, Scalable Process to Generate the Western Fragment. Organic Process Research & Development, 27(12), 2240-2249. https://doi.org/10.1021/acs.oprd.3c00249
Vancouver
Algera RF, Allais C, Baldwin AF, Becirovic H, Bowles P, Brown AR, et al. Synthesis of Nirmatrelvir: Development of an Efficient, Scalable Process to Generate the Western Fragment. Organic Process Research & Development. 2023;27(12):2240-2249. doi:10.1021/acs.oprd.3c00249
BibTeX
@article{Algera2023,
author = {Algera, Russell F. and Allais, Christophe and Baldwin, Aaron F. and Becirovic, Husein and Bowles, Paul and Brown, Adam R. and Buske, Jamie M. and Clarke, Hugh J. and Do, Nga M. and Doyle, Kevin and Fifer, Jonathan and Gray, Kaitlyn and Happe, Alan and Hardink, Mark and Hubbell, Aran K. and James, Chintelle and Khadamkar, Hrushikesh P. and Magano, Javier and McInturff, Emma L. and Mustakis, Jason and Ozbuyukkaya, Gizem and Piper, Jared L. and Place, David W. and Ragan, John A. and Rauschenberger, Blake and Reyes, Giselle and Shehadeh, Rawan and Stanchina, Corey and Stanley, Michael and Weekly, R. Matthew and Weinstein, Ethan and Weisenburger, Gerald A. and Wood, Ethan and Yayla, Hatice G. and Yu, Shu},
title = {Synthesis of Nirmatrelvir: Development of an Efficient, Scalable Process to Generate the Western Fragment},
journal = {Organic Process Research & Development},
year = {2023},
volume = {27},
number = {12},
pages = {2240--2249},
doi = {10.1021/acs.oprd.3c00249}
}
EUVIMED